All News

With all of the negative sentiment surrounding the financial markets, is it appropriate to simply avoid them until things improve?

Aggressive treatment for early-stage bladder cancer does not appear to benefit patients with the disease and may even increase the likelihood for later intervention compared with less-intensive treatment.

Researchers at the University of California, San Francisco have developed a new surgical approach they call a "T-shunt" that appears to resolve ischemic priapism efficiently and effectively with minimal morbidity.

Waiting time to nephrectomy is not a predictor of the recurrence of renal cell carcinoma.

A significant number of patients undergoing open or robotic radical prostatectomy have unrealistic expectations about postoperative sexual function.

The substantial decrease in the use of LHRH agonists in the U.S. since 2004 may not be entirely explained by a recent reduction in physician reimbursement.

Urology Times has received two awards for cover design in recent national journalism competitions.

Mylan Pharmaceuticals Inc., Sun Pharmaceutical Industries, and Sandoz Inc. have received FDA approval for their generic formulations of bicalutamide tablets, 50 mg.

Micheal Chehval, MD, has been appointed chief of urology at Saint Louis University School of Medicine.

American Medical Systems, Inc. has received FDA approval for the AMS 700 with Inhibizone as the only inflatable penile prosthesis with clinical evidence showing a significant reduction in the rate of revision surgery due to infection.

Treatment with sunitinib malate (Sutent) appears to prolong progression-free and overall survival, and is safe and well tolerated in advanced kidney cancer patients with a poor prognosis, including the elderly and those whose cancer has spread to the brain, according to a study to be published in The Lancet Oncology.

Treatments for prostate cancer are among 100 health topics that should receive priority attention and funding from a new national research effort to identify which health care services are most effective.

John Wertman has been appointed government relations and advocacy manager, states and sections, for AUA?s expanded government relations program.

Prostate cancer patients who receive brachytherapy and remain free of disease for 5 years are unlikely to have a recurrence at 10 years, according a new study by researchers from Mount Sinai Medical Center, New York.

Patients with inherited forms of advanced prostate, breast, and ovarian cancers caused by mutations in the BRCA1 and BRCA2 genes experienced tumor shrinkage without major side effects when treated with the investigational drug olaparib (AZD-2281), a recently published phase I study showed.

Caldera Medical, Inc. (Agoura Hills, CA) has received FDA clearance for the Ascend Pelvic Floor Repair System with Apical Support for female pelvic organ prolapse treatment.

The FDA is requiring manufacturers of two prescription topical testosterone gel products, AndroGel 1% and Testim 1%, to include a boxed warning on the products? labels after receiving reports of adverse effects in children who were inadvertently exposed to testosterone through secondary exposure.

The FDA is requiring manufacturers of two prescription topical testosterone gel products, AndroGel 1% and Testim 1%, to include a boxed warning on the products? labels after receiving reports of adverse effects in children who were inadvertently exposed to testosterone through secondary exposure.

Increases in urologists? overall compensation did not keep up with inflation in 2008, according to a survey by the Medical Group Management Association. The same finding held true for several other physician specialties and primary care providers.

360 Network

Severe vaginal vault prolapse affects more than 3 million women in the United States, and 11% of women will require prolapse or incontinence surgeries in their lifetime. This article discusses the range of evolving surgical options for repairing rectocele, cystocele, and enterocele, with an emphasis on techniques using synthetic mesh.

Further analysis of the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial will help answer important questions and direct therapy.

RPLND alone provides up to 90% cure in patients with low-volume, low-risk testis cancer and eliminates the risk of teratoma and viable tumor in the retroperitoneum in those with high-risk disease.

New Products

Results of a milestone study on the use of an experimental form of immunotherapy may usher in a new era in the management of androgen-independent prostate cancer.

Ureteroscopy is more effective than extracorporeal shock wave lithotripsy for the treatment of proximal ureteral stones.

With the current physician shortage, if you plan to bring another physician into the practice, you'd better do it right.